Urinary biomarkers at early ADPKD disease stage.
BACKGROUND:Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a decline in renal function at late disease stage when the majority of functional renal parenchyma is replaced by cystic tissue. Thus, kidney function, assessed by estimated glomerular filtration rate (eGFR) does not...
Main Authors: | Katja Petzold, Diane Poster, Fabienne Krauer, Katharina Spanaus, Gustav Andreisek, Thi Dan Linh Nguyen-Kim, Ivana Pavik, Thien Anh Ho, Andreas L Serra, Laura Rotar |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4395321?pdf=render |
Similar Items
-
Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial.
by: Matthias Braun, et al.
Published: (2012-01-01) -
Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study
by: Wüthrich Rudolf P, et al.
Published: (2007-09-01) -
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study.
by: Andreas D Kistler, et al.
Published: (2013-01-01) -
Correction: Urinary Proteomic Biomarkers for Diagnosis and Risk Stratification of Autosomal Dominant Polycystic Kidney Disease: A Multicentric Study.
by: Andreas D. Kistler, et al.
Published: (2013-01-01) -
Polycystins, ADPKD, and Cardiovascular Disease
by: Ivana Y. Kuo, et al.
Published: (2020-04-01)